bioMérieux America CEO Talks Dx Reform Progress, Antibiotic Resistance

27 Jun 2018

• By Sue Darcey

Stefan Willemsen, a top executive at diagnostics firm bioMérieux, has been working through AdvaMedDx with FDA, and with US House members to signal industry support for a bill to create a separate diagnostic regulatory framework at FDA. He spoke about that effort and explained how his firm’s products can be helpful in pinpointing cases of antibiotic resistance.

The IVD test-kit industry is working closely with US FDA and Congress on legislation to reform the regulation of diagnostics. Stefan Willemsen, CEO of the US subsidiary of French diagnostics firm bioMérieux, spoke about that effort and the firm's focus on fighting antibiotic overuse in an interview with Medtech Insight.

Willemsen, along with other AdvaMedDx board members, met with lawmakers from the US House of Representatives and FDA device-center chief...